Article Type: Generic

First in Canada

The Univ of Ottawa is initiating the first program of its kind in Canada to provide intellectual property (IP) from its faculty of engineering on a three-year royalty-free basis to small Ottawa-area companies.

“National Priorities and Regional Advantages:
Opportunities for Atlantic Canada in Canada’s Science and Technology Strategy”
November 21, 2007
World Trade Centre, Halifax, Nova Scotia

FMI: www.researchmoneyinc.

U of T dean to chair expert panel

The federal government has taken the first steps towards establishing a regulatory regime for nanotechnology. The Council of Canadian Academies (CCA) has secured the services of Dr Pekka Sinervo to lead an expert panel on the potential health and environmental risk of nanotechnology.

A cloak of silence has been drawn over discussions by Atomic Energy of Canada Ltd (AECL) to sell a stake of its commercial CANDU reactor business to the private sector. Recent media reports say that talks are underway sell a 49%-stake of the CANDU business to General Electric.

Microsoft Corp’s decision to open a new software development centre in Canada is being hailed as a coup for this country’s relatively liberal immigration policies and an endorsement of its growing reputation as a more tolerant and welcoming nation compared to its neighbour to the south.

Canada’s information and communications technology (ICT) sector, while modest by global standards, is a significant contributor to the Canadian economy, with more than 32,000 firms employing nearly 600,000 people and contributing $52.

Private subsidiary in the works

CMC Microsystems has reached deep from within the microelectronics sector and selected Dr Ian McWalter as its new president and CEO, indicating a move towards increased commercialization as it continues implementation of its 2004 strategic plan.

Canadian surface science has received a major boost with the official unveiling of a new reflectometer at the National Research Council’s Canadian Neutron Beam Centre (CNBC) in Chalk River ON. The $2.

Tissue Regeneration Therapeutics Inc (TRT) has landed a lucrative US licensing deal that could see the Toronto-based start-up become a world-leading supplier of mesenchymal stem/progenitor cells to cord blood banks around the world.

The federal government has announced its flagship program for increasing private sector investment in research and greater collaboration between university-based researchers and the business community.